PrimeRFP SCOUT · Federal Contract Recompete Brief

36C77021N0214Pharmaceutical - naloxone 4mg NASAL SPRAY — Adapt Pharma Inc

Adapt Pharma Inc holds $753K across 16 federal awards, concentrated at Department of Homeland Security (DHS). This PIID sits alongside 1 related award under parent V797D70052. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 7, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

National Cmop Office (36C770)

Awarding office

Adapt Pharma Inc

Recipient

Sep 7, 2021

PoP end

$679K

Obligated

$679K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Adapt Pharma Inc — $90

Contract facts

Federal

Contract number36C77021N0214

Also listed as36C770-21-N-0214

Also listed asV797D70052-36C77021N0214

AgencyNational Cmop Office (36C770)

Awarding officeNational Cmop Office (36C770)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentAdapt Pharma Inc

CAGE7ARJ9

UEIQ1MZNNSQUJ53

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVV797D70052

Place of performancePLYMOUTH MEETING PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 1, 2021

PoP end (current)Sep 7, 2021

Obligated$679K

Current value$679K

Potential value$679K

PHARMACEUTICAL - NALOXONE 4MG NASAL SPRAY SOLUTION FOR HINES CMOP is a federal award for National Cmop Office (36C770) held by Adapt Pharma Inc. Estimated value $679K ($679K obligated). Current period of performance ends Sep 7, 2021. Last award drew 1 bidder. Place of performance: PLYMOUTH MEETING PA.

PHARMACEUTICAL - NALOXONE 4MG NASAL SPRAY SOLUTION FOR HINES CMOP

Recompete timing

Public

● Past PoP end (1809 days ago)

Current PoP ended Sep 7, 2021 (1809 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Adapt Pharma Inc — $753K obligated across 16 awards (firm-wide, all agencies) · lead buyer Department of Homeland Security (DHS).

% of firm-wide obligated ($753K) · all agencies

Department of Homeland Security (DHS)$473K · 63%Department of State (DOS)$285K · 38%

Related awards

Same parent · incumbent

19AQMM26P0604

NARCAN NASAL SPRAY DEVICES

$285K

Jun 1, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C77021N0214?

36C77021N0214 (Pharmaceutical - naloxone 4mg NASAL SPRAY) is a National Cmop Office (36C770) award with a potential value of $679K, currently held by Adapt Pharma Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C770-21-N-0214?

36C770-21-N-0214 is the dashed form of PIID 36C77021N0214 (Pharmaceutical - naloxone 4mg NASAL SPRAY), held by Adapt Pharma Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C77021N0214?

National Cmop Office (36C770) awarded 36C77021N0214 to Adapt Pharma Inc (potential $679K).

Who is the incumbent on 36C77021N0214?

Adapt Pharma Inc is the incumbent with $753K across 16 related awards in SCOUT’s public footprint. The current period of performance ends Sep 7, 2021.

When does Adapt Pharma Inc’s 36C77021N0214 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 7, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 1, 2026 · refreshed monthlyLatest procurement action Sep 1, 2021